An Angiogenic Switch in Macrophages Involving Synergy between Toll-Like Receptors 2, 4, 7, and 9 and Adenosine A2A Receptors

Autor: Geert-Jan Boons, György Haskó, Madhuri Ramanathan, Grace Pinhal-Enfield, S. Joseph Leibovich, Stefanie N. Vogel, Andrew L. Salzman
Rok vydání: 2003
Předmět:
Lipopolysaccharides
Male
Vascular Endothelial Growth Factor A
Adenosine
Vasodilator Agents
Adenosine A2A receptor
Angiogenesis Inhibitors
Adenosine-5'-(N-ethylcarboxamide)
Endothelial Growth Factors
Pharmacology
Mice
Enzyme Inhibitors
Receptor
Cells
Cultured

Mice
Knockout

Lymphokines
Toll-like receptor
Membrane Glycoproteins
Vascular Endothelial Growth Factors
Toll-Like Receptors
NF-kappa B
Up-Regulation
DNA-Binding Proteins
Intercellular Signaling Peptides and Proteins
medicine.drug
Agonist
medicine.medical_specialty
Paclitaxel
Receptor
Adenosine A2A

medicine.drug_class
Lipoproteins
Neovascularization
Physiologic

Receptors
Cell Surface

Biology
Pathology and Forensic Medicine
Internal medicine
Purinergic P1 Receptor Agonists
medicine
Animals
Humans
Tumor Necrosis Factor-alpha
Adenine
Receptors
Purinergic P1

Toll-Like Receptor 2
Toll-Like Receptor 3
Mice
Inbred C57BL

Toll-Like Receptor 4
Toll-Like Receptor 5
TLR2
Endocrinology
Toll-Like Receptor 7
Toll-Like Receptor 9
Macrophages
Peritoneal

TLR4
Regular Articles
Zdroj: The American Journal of Pathology. 163:711-721
ISSN: 0002-9440
DOI: 10.1016/s0002-9440(10)63698-x
Popis: Adenosine A(2A) receptor (A(2A)R) agonists synergize with Escherichia coli (E. coli) LPS [toll-like receptor (TLR)4 agonist] to up-regulate vascular endothelial growth factor (VEGF) expression in murine macrophages. Here, we demonstrate that TLR2, TLR7, and TLR9, but not TLR3 and TLR5 agonists, also synergize with A(2A)R agonists and adenosine to up-regulate VEGF, while simultaneously strongly down-regulating TNFalpha expression. In the absence of adenosine or A(2A)R agonists, Porphyromonas gingivalis (P. gingivalis) LPS and PAM(3)CAG (TLR2 agonists), resiquimod (R848) (TLR7 agonist), and non-methylated CpG DNA (TLR9 agonist) strongly up-regulate TNFalpha expression, with no effect on VEGF. In the presence of adenosine or A(2A)R agonists, but not A(1)R agonists, TLR2, 4, 7, and 9 agonists strongly up-regulate VEGF expression, while simultaneously down-regulating TNFalpha. C57BL/10ScN (TLR4 deletion mutant) macrophages produce TNFalpha in response to TLR2, 3, 7, and 9 agonists, but not the TLR4 agonist E. coli LPS. With adenosine or A(2A)R agonists, TLR2, 7, and 9, but not TLR4 agonists, also synergistically up-regulate VEGF, while down-regulating TNFalpha expression. Polyinosinic-polycytidilic acid (poly(I:C)) (TLR3 agonist) stimulates TNFalpha expression in macrophages from both C57BL/10ScSn and C57BL/10ScN mice, but has little effect on VEGF expression in the presence of adenosine or A(2A)R agonists. R-flagellins from Serratia marcescens (S. marcescens) and Salmonella muenchen (S. muenchen) do not stimulate TNFalpha expression in either C57BL/10ScSn or C57BL10/ScN mice, and have no effect on VEGF production in the presence of adenosine or A(2A)R agonists. While adenosine and A(2A)R agonists strongly down-regulate TNFalpha protein expression induced by TLR2, 3, 4, 7, and 9 agonists, TNFalpha mRNA and NF-kappaB activation are not reduced. We propose a novel signaling pathway in murine macrophages involving synergy between TLRs 2, 4, 7, and 9 and A(2A)Rs, that up-regulates VEGF and down-regulates TNFalpha expression, thus acting as an angiogenic switch. This angiogenic switch may play an important role in ischemia when TLR agonists are present, providing an interface between innate immunity and wound healing.
Databáze: OpenAIRE